These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 1450043)
61. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia. Hostutler RA; Chew DJ; Jaeger JQ; Klein S; Henderson D; DiBartola SP J Vet Intern Med; 2005; 19(1):29-33. PubMed ID: 15715044 [TBL] [Abstract][Full Text] [Related]
62. The use of pamidronate in three children with renal disease. Sellers E; Sharma A; Rodd C Pediatr Nephrol; 1998 Nov; 12(9):778-81. PubMed ID: 9874327 [TBL] [Abstract][Full Text] [Related]
63. Pamidronate (Aredia, Ciba) in malignant hypercalcaemia. MacConnachie AM Intensive Crit Care Nurs; 1997 Feb; 13(1):58-9. PubMed ID: 9095884 [TBL] [Abstract][Full Text] [Related]
64. Pamidronate-induced irreversible symptomatic hypocalcemia in a dog with hypercalcemia after glucocorticoid withdrawal: a case report. Oh YI; An JH; Lim GH; Park SM; Kim TH; Seo KW; Youn HY BMC Vet Res; 2024 May; 20(1):227. PubMed ID: 38790012 [TBL] [Abstract][Full Text] [Related]
65. Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate). Oliveri B; Mastaglia SR; Mautalen C; Gravano JC; Pardo Argerich L Acta Paediatr; 2004 Jul; 93(7):1002-3. PubMed ID: 15303821 [TBL] [Abstract][Full Text] [Related]
67. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Walls J; Ratcliffe WA; Howell A; Bundred NJ Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531 [TBL] [Abstract][Full Text] [Related]
71. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. McIntyre HD; Cameron DP; Urquhart SM; Davies WE Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602 [TBL] [Abstract][Full Text] [Related]
72. The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication. Lee DC; Lee GY J Toxicol Clin Toxicol; 1998; 36(7):719-21. PubMed ID: 9865241 [TBL] [Abstract][Full Text] [Related]
73. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Gurney H; Grill V; Martin TJ Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988 [TBL] [Abstract][Full Text] [Related]
74. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment. Gibbs CJ; Peacock M Postgrad Med J; 1986 Oct; 62(732):937-8. PubMed ID: 3774726 [TBL] [Abstract][Full Text] [Related]
75. Acute management of cancer-related hypercalcemia. Chisholm MA; Mulloy AL; Taylor AT Ann Pharmacother; 1996 May; 30(5):507-13. PubMed ID: 8740333 [TBL] [Abstract][Full Text] [Related]
76. Treatment of hypercalcaemia of malignancy. Heath DA Baillieres Clin Endocrinol Metab; 1990 Mar; 4(1):139-45. PubMed ID: 2143893 [TBL] [Abstract][Full Text] [Related]
77. Safety of pamidronate in patients with renal failure and hypercalcemia. Machado CE; Flombaum CD Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358 [TBL] [Abstract][Full Text] [Related]
78. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy. Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762 [TBL] [Abstract][Full Text] [Related]
79. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia. Sekine M; Takami H Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321 [TBL] [Abstract][Full Text] [Related]
80. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Wüster C; Schöter KH; Thiébaud D; Manegold C; Krahl D; Clemens MR; Ghielmini M; Jaeger P; Scharla SH Bone Miner; 1993 Aug; 22(2):77-85. PubMed ID: 8251767 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]